Challenge: In recent years, a growing number of cancer patients have been treated with therapies targeting specific genetic alterations present in their tumors. Generally, this is done in combination with traditional chemotherapeutic agents that represent the standard of care. However, a systematic analysis to identify the most appropriate combination of chemo and targeted therapy to…
Challenge: It has become increasingly clear that breast cancer progression, response to therapy and ultimately disease outcomes are determined not only by features of the tumour itself, but also by characteristics of, and interactions with the surrounding tissue, or stroma. Currently, stromal information is not used for patient stratification in clinical setting, trial design or…
Challenge: A major challenge in cancer therapy is to stop cancer cells before they metastasize to other tissues, at which point the disease may become resistant to therapeutic intervention. During cancer progression, circulating tumor cells (CTCs) are shed from the primary tumor or its metastatic sites and their number follow closely the progression of the…
MONTREAL, Canada, July 18, 2023 – The Neuro-CERVO Alliance has teamed up with Simmunome, a Montreal-based artificial intelligence company, to understand the mechanisms of neurological diseases and accelerate drug development. The recent Neuro-CERVO Alliance for Drug Discovery (ANCDM) initiative welcomes a new Montreal-based private partner, Simmunome, to unravel biological pathways and identify biomarkers involved in…
Challenge: One of the major challenges for disease treatment is the identification of efficacious drug targets. To overcome the problem, one proposed solution is the use of combined drug therapy that either targets two genes simultaneously or interfere with a single gene with loss-of-function of another one. In both cases this will induce cell synthetic…
Challenge: Galectins are a family of lectin proteins implicated in tumor progression and immune evasion. When produced in excess by cancer cells, galectins can form homodimers and bind glycans on the surface of T cells. This suppresses the local and systemic immune response in patients, helping tumors to escape immune surveillance and limiting the efficacy…
Challenge: Triple negative breast cancer (TNBC) accounts for 15 to 20% of diagnosed breast tumors. This type of breast cancer is particularly aggressive and associated with a high risk of recurrence, especially in the first five years after diagnosis. TNBC treatment is limited to chemotherapy that can be combined with surgery and/or radiotherapy. Targeted therapy…
Challenge: Classical medical Avatar models involve implanting patient tumor samples in immunodeficient mice for subsequent drug testing to tailor the optimal drug or combination of drugs to a given patient. This strategy proves to be an excellent approach for personalized medicine in various cancer indications such as melanoma, lung cancer, and breast cancer. Nevertheless, this…
Challenge: Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. Even in the early stages it is treated primarily by chemotherapy, often before surgery. The presence of remaining tumor after chemotherapy signals chemoresistance and poor prognosis resulting in the death of 30 to 40 % of patients with triple negative breast…
Challenge: Solid tumor growth is regulated by complex interactions of tumor cells with an assortment of adjacent non-malignant cells collectively referred to as the tumor microenvironment (TME). In “triple-negative breast cancer” (TNBC), which represents 15 to 20 % of all breast cancers, tumors can be characterized as “immune hot” or “immune cold” with respect to…